Federal law divides controlled substances into drug schedules 1 through 5, ranked by abuse potential, accepted medical use, and risk of dependence. Schedule I is the tightest category, reserved for drugs the government treats as having no accepted medical use, and Schedule V is the loosest, covering medications with the lowest abuse risk. Where a drug sits on that ladder decides whether a doctor can prescribe it, how a pharmacy can dispense it, and how much prison time a conviction can carry.
Schedule I
Schedule I is reserved for substances that meet all three of the strictest criteria: high potential for abuse, no currently accepted medical use in the United States, and no accepted safe use even under medical supervision. Doctors cannot prescribe them. They sit outside the medical system entirely.
Common examples include heroin, LSD, peyote, ecstasy (MDMA), and methaqualone.
Marijuana remains on Schedule I as of mid-2026, though its placement is actively contested. In May 2024, the Department of Justice published a notice of proposed rulemaking to move marijuana to Schedule III, following a Department of Health and Human Services recommendation that it has a currently accepted medical use. A hearing on the proposed rescheduling is set to begin on June 29, 2026.
Schedule II
Schedule II drugs share the “high potential for abuse” label with Schedule I, but they have a currently accepted medical use. Abuse can lead to severe psychological or physical dependence, so they carry the tightest prescribing rules of any medications available through a pharmacy.
This schedule includes some of the most prescribed and most misused medications in the country: oxycodone (OxyContin), hydromorphone (Dilaudid), fentanyl, methadone, meperidine (Demerol), amphetamine (Adderall), and methylphenidate (Ritalin). Cocaine and methamphetamine also sit here because they retain narrow medical applications.
A Schedule II prescription cannot be refilled. Once the pharmacy fills it, the patient needs a new prescription for more medication. To spare patients on stable long-term regimens from constant office visits, federal regulations allow a practitioner to issue up to three separate prescriptions at a single visit covering a 90-day supply, with each marked with the earliest date a pharmacy may fill it. The practitioner has to determine that doing so does not create an undue risk of diversion or abuse, and state law has to permit the practice as well.
Schedule III
Schedule III drugs have a lower abuse potential than Schedules I and II, carry a currently accepted medical use, and their abuse may lead to moderate or low physical dependence or high psychological dependence. The regulatory burden is noticeably lighter than for Schedule II.
Examples include codeine combination products containing less than 90 milligrams per dosage unit (such as Tylenol with codeine), ketamine, anabolic steroids like testosterone, and certain buprenorphine products used in opioid addiction treatment.
Prescriptions can be refilled up to five times within six months of the original date. After that, the patient needs a new prescription. Oral prescriptions are permitted, unlike the written-only requirement for most Schedule II drugs.
Schedule IV
Schedule IV substances have a low abuse potential relative to Schedule III, and their abuse leads to limited physical or psychological dependence. This category covers some of the most widely prescribed medications in the country: alprazolam (Xanax), diazepam (Valium), zolpidem (Ambien), tramadol, lorazepam (Ativan), and carisoprodol (Soma). They still require a prescription and carry the same refill limits as Schedule III: five refills within six months.
Schedule V
Schedule V sits at the bottom of the regulatory ladder. These drugs have the lowest abuse potential and often contain small amounts of narcotics mixed into larger formulations. Typical examples are cough preparations with less than 200 milligrams of codeine per 100 milliliters (such as Robitussin AC), Lomotil, and pregabalin (Lyrica). In some jurisdictions, certain Schedule V preparations can be sold without a prescription, provided a pharmacist handles the transaction under specific conditions.
Federal Penalties for Simple Possession
Federal simple possession penalties under 21 U.S.C. § 844 escalate sharply with each conviction, and they apply regardless of which schedule the drug sits on.
- First offense: up to one year in prison and a minimum fine of $1,000.
- Second offense, with one prior drug conviction: between 15 days and two years in prison and a minimum fine of $2,500.
- Third or subsequent offense, with two or more prior drug convictions: between 90 days and three years in prison and a minimum fine of $5,000.
The mandatory minimum sentences for repeat offenders cannot be suspended or deferred. A convicted person may also be ordered to pay the reasonable costs of the investigation and prosecution on top of fines.
Federal Penalties for Trafficking
Manufacturing, distributing, or possessing with intent to distribute carries far heavier consequences, and here the schedule matters enormously.
For Schedule I and II substances, a first trafficking offense involving threshold quantities can carry a mandatory minimum of 5 to 10 years in prison and fines up to $10 million for an individual. If someone dies or suffers serious bodily injury from the drug, the minimum jumps to 20 years. Prior serious drug felony or violent felony convictions push minimums to 15 or 25 years, with life imprisonment possible.
Trafficking in Schedule III substances carries up to 10 years in prison for a first offense. Schedule IV drops to up to five years. Schedule V tops out at one year. The gap between a Schedule I trafficking conviction and a Schedule V trafficking conviction can be the difference between decades in federal prison and a sentence measured in months.
How a Drug Gets Placed on a Schedule
Before placing a substance on a schedule, moving it, or removing it, the government has to weigh eight factors set out in 21 U.S.C. § 811. They include the drug’s actual or relative potential for abuse, the scientific evidence of its pharmacological effect, the state of current scientific knowledge, the history and current pattern of abuse, the scope and significance of that abuse, the risk to public health, the psychological or physical dependence it can cause, and whether it is an immediate precursor to a substance already controlled. No single factor decides the outcome. A drug with limited abuse history can still be tightly controlled if its pharmacology suggests serious risks, and a widely abused drug can land in a lower schedule if it has clear medical value.
Two other mechanisms let the federal government reach drugs the five schedules do not already cover.
The Federal Analogue Act, 21 U.S.C. § 813, treats any controlled substance analogue intended for human consumption as a Schedule I drug for prosecution purposes, even if it has never been formally scheduled. A substance qualifies if its chemical structure is substantially similar to a Schedule I or II drug and it produces substantially similar effects on the central nervous system, or if someone represents it as producing those effects. The law has been the federal government’s primary tool against waves of designer drugs, from synthetic cannabinoids to novel stimulants marketed as “bath salts.”
Temporary emergency scheduling, under 21 U.S.C. § 811(h), lets the Attorney General place a substance into Schedule I without going through the full scientific evaluation. The order takes effect after 30 days’ notice in the Federal Register, lasts two years, and can be extended by one additional year while permanent scheduling proceedings continue. The government only has to consider three of the eight factors. The DEA used this authority in 2018 to place the entire class of fentanyl analogues in Schedule I, and because Congress has not enacted permanent class-wide scheduling, that temporary order has been extended repeatedly through continuing appropriations acts.
How Schedules Change
The schedules are not permanent. The DEA, HHS, or any interested party, including manufacturers, medical associations, state agencies, and individual citizens, can initiate proceedings to add, move, or remove a substance. The DEA gathers data and requests a scientific and medical evaluation from HHS, which the FDA conducts against the eight scheduling factors. HHS findings on scientific and medical questions are binding on the DEA, and if HHS recommends that a substance should not be controlled at all, the DEA is legally barred from scheduling it. The DEA then conducts its own review, publishes a proposed rule, takes public comment, and may hold hearings before issuing a final rule.
The marijuana proceeding shows how slow this can run. HHS recommended rescheduling to Schedule III, the DEA published its proposed rule in May 2024, and as of mid-2026 the matter is still active, with administrative hearings scheduled to begin in late June 2026 following an executive order directing the Attorney General to complete the rulemaking as expeditiously as possible.